Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology
@article{Buttgereit2002StandardisedNF, title={Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology}, author={Frank Buttgereit and Jos{\'e} Ant{\'o}nio Pereira da Silva and Maarten Boers and Gerd R. Burmester and Maurizio Cutolo and J W G Jacobs and John R. Kirwan and Lars Köhler and Piet L.C.M. van Riel and Thomas L. Vischer and Johannes W J Bijlsma}, journal={Annals of the Rheumatic Diseases}, year={2002}, volume={61}, pages={718 - 722} }
In rheumatology and other medical specialties there is a discrepancy between the widespread use and the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of glucocorticoid treatment regimens used in various phases of diseases vary between countries and institutions. Given this background, a workshop under the auspices of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials was held to discuss this issue and to seek a consensus…
405 Citations
When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations
- MedicineAnnals of the New York Academy of Sciences
- 2014
The place of glucocorticoids in the European League Against Rheumatism recommendations for the management of RA is discussed and the literature that was the basis for these recommendations is reviewed.
Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
- MedicineAnnals of the rheumatic diseases
- 2010
Objective To explore perspectives among patients and rheumatologists on glucocorticoid (GC) therapy and European League Against Rheumatism (EULAR) recommendations on the management of systemic GC…
Glucocorticoids in rheumatoid arthritis: the picture is shaping up
- MedicineAnnals of the rheumatic diseases
- 2017
The view on the most optimal use of these drugs does slowly but constantly maturate, which primarily results from thorough analyses of accumulated data in order to update recommendations, but there are also new and often qualitatively better data coming in to enrich the authors' knowledge.
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
- MedicineAnnals of the rheumatic diseases
- 2007
Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus.
Principles of glucocorticoid therapy
- Medicine
- 2003
Glucocorticoid therapy is one of the most widely used treatments in medicine, hence this volume is intended for “internists and the many subspecialists in internal medicine, as well as family…
Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion.
- MedicineJoint, bone, spine : revue du rhumatisme
- 2010
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
- MedicineAnnals of the rheumatic diseases
- 2013
Nine final recommendations for the management of medium to high-dose systemic GC therapy in rheumatic diseases were selected and evaluated with their strengths of recommendations.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- MedicineAnnals of the rheumatic diseases
- 2014
The 2010 European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and b DMARDs, respectively) have been updated and are intended to improve outcome in patients with RA.
Glucocorticoids for rheumatoid arthritis in the era of targeted therapies.
- MedicineReumatologia clinica
- 2019
Systemic glucocorticoids in rheumatoid arthritis
- Medicine
- 2005
New evidence on the mechanisms of action of glucocorticoids, outcomes of glucOCorticoid treatment and adverse effects are reviewed, and an evidence based approach to their effective use in the management of rheumatoid arthritis is proposed.
References
SHOWING 1-10 OF 22 REFERENCES
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
- MedicineThe New England journal of medicine
- 1995
In patients with early, active rheumatoid arthritis, prednisolone given for two years in addition to other treatments substantially reduced the rate of radiologically detected progression of disease.
Corticosteroids in polymyalgia rheumatica--a review of different treatment schedules.
- MedicineClinical and experimental rheumatology
- 2000
Intramuscular methylprednisolone has been shown to have a similar remission rate to oral steroids and a better side effect profile with respect to fracture rate and weight gain.
Optimizing glucocorticoid therapy in rheumatoid arthritis.
- Medicine, BiologyRheumatic diseases clinics of North America
- 2000
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
- MedicineThe Lancet
- 1997
Systemic Lupus Erythematosus: Emerging Concepts: Part 1: Renal, Neuropsychiatric, Cardiovascular, Pulmonary, and Hematologic Disease
- Medicine, BiologyAnnals of Internal Medicine
- 1995
An overview of recent advances in the pathogenesis of systemic lupus erythematosus and selected topics related to dermatologic and joint disease, as well as issues related to the antiphospholipid antibody syndrome, pregnancy, hormonal therapy, and morbidity and mortality are examined.
Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- MedicineAnnals of Internal Medicine
- 2002
The aim of this study was to investigate the clinical efficacy, disease-modifying properties, and side effects of low-dose glucocorticoids as monotherapy for previously untreated patients with early active rheumatoid arthritis.
Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis
- Medicine, PsychologyAnnals of the rheumatic diseases
- 2001
Qualitatively and quantitatively the short term effects of CPT in patients with active established RA on various dimensions of health status resemble the longterm effects of conventional DMARD treatment in patients With active rheumatoid arthritis.
Management of systemic vasculitis.
- MedicineBest practice & research. Clinical rheumatology
- 2001
This chapter seeks to review the approach to management in selected forms of systemic vasculitis and examines the nature of the disease and its severity, as well as the effectiveness of individual therapeutic regimens.
The Pharmacological Basis of Therapeutics
- Medicine
- 1941
On pharmacology and the rational use of drugs, 42 authors share the herculean task of reviewing the flood of recent literature under single or dual authorship and each chapter offers a complete and up-to-date review.
Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids.
- Medicine, BiologyThe Journal of rheumatology
- 1999
The abnormal androgen concentrations observed during testing in patients with RA might support the implication of adrenal androgens in the immune/inflammatory cytokine mediated mechanisms involved in the pathophysiology and clinical aspects of RA.